Portfolio company IXICO, the brain health company, has signed a new contract worth US$1.2m with a top 15 global pharmaceutical company for advanced imaging clinical trial services in a rare neurodegenerative disease, progressive supranuclear palsy (“PSP”).
The partnership will see the applicaiton of IXICO's TrialTracker™ and Assessa® digital platforms to collect and analyse MRI data in a Phase IIa clinical study of patients in the early stages of PSP. This project will support the development of a first-in-class therapy that could prevent further neurodegeneration in PSP cases. The study is expected to complete in 2019 with the potential to be extended further.
Derek Hill, Chief Executive of IXICO, commented:
“This contract win adds to our portfolio of clinical trials in PSP and validates the differentiation of our unique TrialTracker™ and Assessa® digital platforms with a new global pharma customer. We are pleased with the continued progress we are making to grow and evolve relationships within the pharmaceutical industry demonstrating our expertise across a range of neurological indications.”